Revance Therapeutics Inc (DELISTED) (RVNC:DL)
3.65
0.00 (0.00%)
USD |
NASDAQ |
Feb 06, 16:00
Revance Therapeutics Enterprise Value: 630.01M for Feb. 6, 2025
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Regeneron Pharmaceuticals, Inc. | 73.01B |
| BioAge Labs, Inc. | 442.76M |
| Ligand Pharmaceuticals, Inc. | 3.713B |
| Cellectar Biosciences, Inc. | -3.606M |
| Hepion Pharmaceuticals, Inc. | 0.2183M |
Enterprise Value Related Metrics
| Gross Profit Margin (Quarterly) | 70.55% |
| Profit Margin (Quarterly) | -63.65% |
| Earnings Yield | -53.15% |
| Normalized Earnings Yield | -92.04 |